ELI LILLY & Co is 473.0x more valuable than Ultragenyx Pharmaceutical Inc. by market capitalization ($1.070 T vs $2.26 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RARE | LLY |
|---|---|---|
| Market cap | $2.26 B | $1.070 T |
| US-listed rank | #2014 | #10 |
| Revenue (latest FY) | $673.00M | $65.18B |
| Net income (latest FY) | -$575.00M | $20.64B |
| Net margin | -85.4% | 31.7% |
| P/E (trailing FY) | - | 51.8 |
| SEC filings | 1,100 | 989 |
ELI LILLY & Co is 473.0x more valuable than Ultragenyx Pharmaceutical Inc. by market capitalization ($1.070 T vs $2.26 B).
In their latest fiscal years, Ultragenyx Pharmaceutical Inc. reported $673.00M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Ultragenyx Pharmaceutical Inc. and ELI LILLY & Co, or browse the full rankings.